Literature DB >> 13680071

Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder.

Don R Cherek1, Oleg V Tcheremissine, Scott D Lane, Cynthia J Pietras.   

Abstract

RATIONALE: The possible role of GABA in human aggression was evaluated by administering gabapentin to subjects with and without a history of conduct disorder and comparing the effects on laboratory measures of aggression and escape.
METHODS: Eighteen male and two female subjects with a history of criminal behavior participated in experimental sessions, which measured aggressive and escape responses. Ten subjects had a history of childhood conduct disorder (CD+) and ten subjects with no history (non-CD controls). Aggression was measured using the Point Subtraction Aggression Paradigm (PSAP), which provided subjects aggressive, escape and monetary reinforced response options.
RESULTS: Acute doses (200, 400 and 800 mg) of gabapentin had similar effects on aggressive responses among CD+ subjects compared to non-CD control subjects. Aggressive responses of CD+ and non-CD control subjects increased at lower gabapentin doses, and decreased at the highest 800 mg gabapentin dose. Gabapentin increased escape responses for both CD+ and non-CD controls CD- subjects at the lowest dose, but then produced dose-related decreases at the two higher doses in both groups. No changes in monetary reinforced responses were observed, indicative of no CNS stimulation or sedation.
CONCLUSIONS: Gabapentin produced similar bitonic effects upon aggressive and escape responses in subjects with and without a history of childhood conduct disorder. This is in marked contrast to prior differential effects of baclofen on aggressive responses between CD+ and non-CD control subjects in a previous study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680071     DOI: 10.1007/s00213-003-1590-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain.

Authors:  C J LaBuda; P N Fuchs
Journal:  Neurosci Lett       Date:  2000-08-25       Impact factor: 3.046

2.  Effectiveness of gabapentin for the treatment of behavioral disorders in dementia.

Authors:  N Herrmann; K Lanctôt; M Myszak
Journal:  J Clin Psychopharmacol       Date:  2000-02       Impact factor: 3.153

3.  Effects of the potentiation of the GABAergic neurotransmission in the olfactory bulbs on mouse-killing behavior.

Authors:  V Molina; L Ciesielski; S Gobaille; P Mandel
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

4.  Acute effects of baclofen, a gamma-aminobutyric acid-B agonist, on laboratory measures of aggressive and escape responses of adult male parolees with and without a history of conduct disorder.

Authors:  Don R Cherek; Scott D Lane; Cynthia J Pietras; Jennifer Sharon; Joel L Steinberg
Journal:  Psychopharmacology (Berl)       Date:  2002-09-03       Impact factor: 4.530

5.  The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats.

Authors:  F de-Paris; J V Busnello; M R Vianna; J B Salgueiro; J Quevedo; I Izquierdo; F Kapczinski
Journal:  Behav Pharmacol       Date:  2000-04       Impact factor: 2.293

6.  Treatment of episodic behavioral disorders with rapidly absorbed benzodiazepines.

Authors:  J L Griffith
Journal:  J Nerv Ment Dis       Date:  1985-05       Impact factor: 2.254

7.  The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine.

Authors:  L Singh; M J Field; P Ferris; J C Hunter; R J Oles; R G Williams; G N Woodruff
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

8.  The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation.

Authors:  Denise D Ben-Porath; Stuart P Taylor
Journal:  Addict Behav       Date:  2002 Mar-Apr       Impact factor: 3.913

Review 9.  Alcohol, GABAA-benzodiazepine receptor complex, and aggression.

Authors:  K A Miczek; J F DeBold; A M van Erp; W Tornatzky
Journal:  Recent Dev Alcohol       Date:  1997

10.  Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal.

Authors:  S E File; N Andrews
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more
  6 in total

Review 1.  Neuropsychiatry of aggression.

Authors:  Scott D Lane; Kimberly L Kjome; F Gerard Moeller
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  Antiepileptic drugs for the treatment of post-traumatic stress disorder.

Authors:  Heather A Berlin
Journal:  Curr Psychiatry Rep       Date:  2007-08       Impact factor: 5.285

3.  Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior.

Authors:  Joshua L Gowin; Charles E Green; Joseph L Alcorn; Alan C Swann; F Gerard Moeller; Scott D Lane
Journal:  J Psychopharmacol       Date:  2011-07-05       Impact factor: 4.153

4.  Acute topiramate differentially affects human aggressive responding at low vs. moderate doses in subjects with histories of substance abuse and antisocial behavior.

Authors:  Scott D Lane; Joshua L Gowin; Charles E Green; Joel L Steinberg; F Gerard Moeller; Don R Cherek
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

5.  Pharmacologic treatment of impulsive aggression with antiepileptic drugs.

Authors:  Matthew S Stanford; Nathaniel E Anderson; Sarah L Lake; Robyn M Baldridge
Journal:  Curr Treat Options Neurol       Date:  2009-09       Impact factor: 3.598

6.  Molecular correlates of social dominance: a novel role for ependymin in aggression.

Authors:  Lynne U Sneddon; Rupert Schmidt; Yongxiang Fang; Andrew R Cossins
Journal:  PLoS One       Date:  2011-04-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.